US Patent 7776523 Endogenous retroviruses up-regulated in prostate cancer

Patent 7776523 was granted and assigned to Novartis on August, 2010 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Novartis

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

7776523

Date of Patent

August 17, 2010

Patent Application Number

10016604

Date Filed

December 7, 2001

Patent Citations Received

‌

US Patent 12064407 Endogenous retrovirus-k (ERVK) encodes an alternate envelope protein

Patent Primary Examiner

‌

Patrick J. Nolan

Patent abstract

Human endogenous retroviruses of the HML-2 family show up-regulated expression in prostate tumors. This finding can be used in prostate cancer screening, diagnosis and therapy.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7776523 Endogenous retroviruses up-regulated in prostate cancer

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API